Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5217 - PRODIGE67_UCGI33 ARION: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial


29 Sep 2019


Poster Display session 2


Tumour Site

Oesophageal Cancer


Rosine Guimbaud


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


R. Guimbaud1, L. Quero2, V. Vendrely3, D. Tougeron4, K. Benerezy5, E. Samalin6, T. Aparicio7, L. Zitvogel8, J. Selves9, P. Otal10, E.L. Cohen-Jonathan Moyal11, J. Delord12, V. Pezzella13, T. Filleron14, A. Modesto15

Author affiliations

  • 1 Medical Oncology, CHU Toulouse, 31052 - Toulouse/FR
  • 2 Radiotherapy, Hôpital Saint Louis AP-HP, 75010 - Paris/FR
  • 3 Radiotherapy, CHu Bordeaux, 33604 - Pessac/FR
  • 4 Medical Oncology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 5 Medical Oncology, Centre Lacassagne, 31000 - Nice/FR
  • 6 Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 7 Gastroenterology And Digestive Oncology Department, Hôpital Saint Louis AP-HP, 75010 - Paris/FR
  • 8 Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 9 Department Of Pathology, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse, 31059 - Toulouse/FR
  • 10 Department Of Pathology, CHU Toulouse, 31059 - Toulouse/FR
  • 11 Radiotherapy, Institut Universitaire du Cancer -Toulouse- Oncopole, 31000 - toulouse/FR
  • 12 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 13 R&d, Unicancer, 75013 - Paris/FR
  • 14 Biostatistics, Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 15 Radiotherapy, IUCT ONCOPOLE, 31059 - toulouse/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5217


Overall survival (OS) of locally advanced esophageal cancer remains poor with a 5-year survival of 15-34%. The standard treatment is definitive radiotherapy delivered with oxaliplatin-based chemotherapy (RCT). Majority of patients (pts) die due to non-complete response, local recurrence and/or metastatic progression and the efficacy of definitive RCT need to be increased. The immune checkpoint inhibitors, anti-programmed death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1), demonstrated promising antitumor activity and manageable safety profile when used as monotherapy in metastatic esophageal squamous cell carcinoma. PD-L1 expression increased in esophageal cancer pts after neoadjuvant RCT but still associated with poor OS. The immune tumor microenvironment for tumor response has raised novel hypotheses regarding newer immunomodulatory approaches during radiotherapy, especially abscopal effect to improve local and distant outcome. Durvalumab (MEDI4736) is a selective high affinity human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80. We hypothesize that combining durvalumab with RCT can increase local response to treatment and prevent distant metastases.

Trial design

This multicentric, open-label, comparative phase II trial plans to randomize (1:1) 120 pts (≥18 years old, WHO <2, unresectable disease) and evaluates the activity of durvalumab (1500 mg) delivered over 12 months in combination with definitive RCT (IMRT 50 Gy for 5 weeks + FOLFOX4 simplified 1 infusion every 2 weeks during 3 months) compared to definitive RCT alone. Given the lack of safety data from this association, a safety run-in of 6 pts is planned. The main objective is to increase 12-months progression-free survival (PFS) centrally reviewed from 50% to 68% (HR = 0.55). 74 events are necessary to detect this difference with a power of 90% using a one–sided logrank test at 10% level of significance. Main secondary endpoints are safety, PFS and quality of life. Ancillary studies mains to identify biomarkers predicting response to treatment. The first patient will be randomized in May 2019 and 12 sites will recruit pts.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Unicancer GI tumors.




L. Quero: Research grant / Funding (institution): AstraZeneca. E.L. Cohen-Jonathan Moyal: Research grant / Funding (institution): AstraZeneca. A. Modesto: Research grant / Funding (institution): AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.